Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-α in patients with progressive metastatic renal cell carcinoma-Reference-Cited by-同舟云学术

Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-α in patients with progressive metastatic renal cell carcinoma

Published:2003-04-29 Issue:9 Volume:88 Page:1346-1351
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Verra N,Jansen R,Groenewegen G,Mallo H,Kersten M J,Bex A,Vyth-Dreese F A,Sein J,van de Kasteele W,Nooijen W J,de Waal M,Horenblas S,de Gast G C

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/6600915.pdf

Reference26 articles.

1. Bukowski RM (1997) Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 80: 1198–1220

2. Bukowski RM (1999) Immunotherapy in renal cell carcinoma. Oncology (Huntingt) 13: 801–810

3. Bukowski RM (2000) Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma. Semin Oncol 27: 204–212

4. de Gast GC, Klumpen HJ, Vyth-Dreese FA, Kersten MJ, Verra NC, Sein J, Batchelor D, Nooijen WJ, Schornagel JH (2000) Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. Clin Cancer Res 6: 1267–1272

5. Favrot MC, Combaret V, Negrier S, Philip I, Thiesse P, Freydel C, Bijmann JT, Franks CR, Mercatello A, Philip T (1990) Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma. J Biol Response Mod 9: 167–177

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Granulocyte macrophage colony-stimulating factor predicts postoperative recurrence of clear-cell renal cell carcinoma;Oncotarget;2016-03-21

2. Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinoma;BJU International;2011-01-18

3. Endostatin gene therapy enhances the efficacy of IL-2 in suppressing metastatic renal cell carcinoma in mice;Cancer Immunology, Immunotherapy;2010-05-20

4. Local Applications of GM-CSF Induce the Recruitment of Immune Cells in Cervical Low-Grade Squamous Intraepithelial Lesions;American Journal of Reproductive Immunology;2010-03

5. Clinical outcome of combined immunotherapy with interferon-α and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma;Urologic Oncology: Seminars and Original Investigations;2009-11